Board of DirectorsJean-Jacques Bienaimé Chief Executive Officer
BioMarin Pharmaceutical Inc.
Mr. Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $3.5 billion in May 2008. BioMarin 2008 revenues around $300 million and is a fully integrated biopharmaceutical company with nearly 700 employees. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief executive officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor's revenues increased substantially to over $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of over $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, he worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.
Mr. Bienaimé is Chairman of the Board of Directors of NeurogesX, Inc., and is a member of the Advisory Board of Bellevue Asset Management's BioVentures II fund. He received an M.B.A from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Superieure de Commerce de Paris.Kenneth M. Bate Independent Consultant
Mr. Bate joined our Board in September 2010. He is currently an independent consultant. From May 2009, he served as President and Chief Executive Officer of Archemix, Inc., a privately-held biotechnology company engaged in discovering and developing aptamer therapeutics to treat chronic and acute diseases. In March 2011, he was elected Non-Executive Chairman of Cubist Pharmaceuticals, Inc., a biopharmaceutical company. From 2006 to April 2009, Mr. Bate served in various positions at NitroMed, Inc., most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Chief Financial Officer of Millennium Pharmaceuticals where he headed the commercial organization. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, he was with Biogen (now Biogen Idec) first as their Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate received his B.A. in Chemistry from Williams College and his M.B.A. from the Wharton School of the University of Pennsylvania. He is currently serving on the boards of AVEO Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc. and a private medical device company.Michael Grey Venture Partner, Pappas Ventures;
President and Chief Executive Officer,
Lumena Pharmaceuticals, Inc.
Mr. Grey joined our Board in December 2005. He has been serving as Venture Partner with Pappas Ventures since January 2010 and as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a privately-held biotechnology company since February 2011. Between January and September 2009, he served as President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a publicly held biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and Board member of Trega Biosciences, Inc., a biotechnology company. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc. From 1974 to 1993, he served in various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Mr. Grey is currently a director of Horizon Pharma, Inc. and Selventa, Inc. Mr. Grey previously served on the board of directors of three public companies during the past five years: SGX Pharmaceuticals, Inc. (from 2001 to 2008), IDM Pharma, Inc. (from 1999 to 2009) and Achillion Pharmaceuticals, Inc. (from 2001 to 2010). He received a B.Sc. in chemistry from the University of Nottingham, United Kingdom.Elaine J. Heron, Ph.D. Chairman and Chief Executive Officer,
Amplyx Pharmaceuticals, Inc.
Dr. Heron joined our Board in July 2002 and serves as the Chairman of the Corporate Governance and Nominating Committee. In February 2009, Dr. Heron became Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company. From July 2001 to October 2008, Dr. Heron was Chairman and Chief Executive Officer of Labcyte Inc., a private biotechnology company and continues to serve on its board of directors. Before joining Labcyte Inc., she spent six years in increasingly responsible positions at the Applied Biosystems Group of Applera Corporation, including the position of General Manager and Vice President of Sales and Marketing. Dr. Heron also serves on the board on Fluxion Biosciences, Inc., a privately held biotech company. Dr. Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.Pierre Lapalme Former President and Chief Executive Officer,
Ethypharm, Inc., North America
Mr. Lapalme joined our Board in January 2004 and was named as Chairman in August 2004. From 1995 until his retirement in 2003, he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including Chief Executive Officer and Chairman of the Board of Rhône-Poulenc Pharmaceuticals, Inc. in Canada, and Senior Vice President and General Manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. (now known as Sanofi-Aventis), where he oversaw the development of the ethical pharmaceutical business in the United States, Canada, Mexico, and Central America. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting patent protection for pharmaceuticals. Mr. Lapalme previously served on the board of directors of two public companies during the past five years: Sciele Pharmaceuticals Inc. (from 1998 to 2008) and Bioxel Pharma (from 2004 to 2009). He also serves on the board of two private biotech companies and was appointed to the board of Aeterna Zentaris in December 2009. Mr. Lapalme studied at the University of Western Ontario and INSEAD France.V. Bryan Lawlis, Ph.D. President and Chief Executive Officer,
Itero Biopharmaceuticals, Inc.
Dr. Lawlis joined our Board in June 2007. He is a founder and currently serves as the President and Chief Executive Officer of Itero Biopharmaceuticals, Inc., a privately held, early stage biopharmaceutical company that was founded in 2006. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation from August 2004, and served on its Board of Directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc. and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State University. In addition to BioMarin Pharmaceutical Inc., Dr. Lawlis holds board positions on two privately held companies, Itero Biopharmaceuticals, Inc. and Sutro Biopharma, Inc.Alan J. Lewis, Ph.D. Chief Executive Officer and Director,
Dr. Lewis joined our Board in June 2005 and serves as the Chairman of the Compensation Committee. Since October 2012, Dr. Lewis has served as Chief Executive Officer and Director of Medistem, Inc., a privately held biotechnology company. From July 2010 to November 2011, Dr. Lewis served as President, Chief Executive Officer and Director of Ambit Biosciences, a privately held biotechnology company. From January 2009 to June 2010, Dr. Lewis served as President and Chief Executive Officer of The Juvenile Diabetes Research Foundation. From February 2006 until December 2008, Dr. Lewis was the President and Chief Executive Officer of Novocell, Inc, a privately held regenerative disease biotechnology company. Prior to joining Novocell, Inc., starting in 2000, he was President of Celgene Signal Research, a wholly owned subsidiary of the Celgene Corporation, a pharmaceutical company.
From February 1994 to August 2000, he was the President and Chief Executive Officer of
Signal Pharmaceuticals, Inc., where he guided the company to its successful acquisition
by Celgene Corporation. From 1979 to 1994, Dr. Lewis held a number of positions at
Wyeth-Ayerst Research and its predecessor, Wyeth Laboratories, Inc., including Vice
President of Research at Wyeth-Ayerst Research. Dr. Lewis has published over 120 full
manuscripts and has written and edited seven books. Dr. Lewis was a Research Associate at
Yale University from 1972 to 1973. Dr. Lewis received a B.Sc. in physiology and biochemistry
from Southampton University, Southampton, Hampshire, U.K. and a Ph.D.
in pharmacology from the University of Wales, Cardiff, U.K. Dr. Lewis currently serves as
director of two private companies, Cytochroma, Inc. and Cellastra.
Mr. Meier joined our Board in December 2006 and serves as the Chairman of the Audit Committee.
He is currently providing management and financial advisory services to medical device and
biopharmaceutical companies, and private equity and venture capital firms.
From January 2010 through March 2012, Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated,
a global medical device company.
From November 2007 to May 2009, Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics,
a global Ophthalmic Medical Device company, that was acquired by Abbott in February 2009.
Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics' Chief Financial Officer,
while serving in a variety of additional senior operating roles, Prior to joining Advanced Medical Optics,
Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc.,
from October 1999, and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining Valeant Pharmaceuticals,
Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's
experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover
Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier is also a Director of Staar Surgical, Inc,
a ophthalmic medical device company, since 2009: and serves on both the Compensation and Audit Committees
Clarus Ventures, San Francisco and Cambridge
Mr. Young joined our Board in September 2010. He is a Ventures Partner at Clarus Ventures, a life science venture capital firm since March 2010 from Monogram Biosciences, a leader in personalized medicine, where he served as Chief Executive Officer from 1999 through to the sale of the company to LabCorp in 2009. Prior to Monogram he was at Genentech since 1980 at positions of increasing responsibility, including Chief Operating Officer responsible for all of the biotechnology company's development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years. Mr. Young received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology. Mr. Young was appointed Chairman of the Board of Biogen Idec in January 2010 and began serving as a Director of IDEC Pharmaceuticals in 1997. He also serves on the Board of Directors at Ariosa Diagnostics, Tandem Diagnostics, Inc., Theravance, Inc., and represents Clarus Ventures as Chairman the Board of TyRx, Inc. and is Executive Chairman of Nanostring Technologies.